Digimarc: AI-Powered Counterfeit Detection for Pharmaceutical Product Authentication

Overview: How Digimarc’s AI-Driven Counterfeit Detection Platform Transforms Drug Safety

Digimarc is an AI-enabled counterfeit-detection platform in the drug-safety category that helps verify the authenticity of pharmaceutical packaging using digitally connected authentication technologies. It addresses the challenge of falsified and diverted medicines by making product verification faster and more practical at the point of use, rather than relying only on downstream checks or centralised inspection.

At a high level, the platform embeds digital watermarks or serialised identifiers into packaging and connects them to web-based, mobile, or back-office authentication workflows. These scans can generate authentication data that is stored for analysis, giving operations teams better visibility into suspicious activity and counterfeiting patterns. For healthcare organisations and supply-chain teams, this can reduce manual verification burden, speed decision-making, and strengthen confidence in product authenticity across distribution channels.

Last checked on 2026-08-01: Digimarc remains active, added provenance and verification infrastructure for AI workflows, and continues to position anti-counterfeiting as part of a broader authentication platform

What is Digimarc?

Digimarc is a digital authentication and anti-counterfeiting platform for the drug safety category that verifies the authenticity of pharmaceutical and other high-value products using embedded digital watermarks and mobile- or cloud-based scanning workflows. It is used by pharmaceutical companies, supply-chain teams, field inspectors, and other organisations that need product authentication and traceability across packaging and distribution channels.

The platform is differentiated by its watermark-based technical approach, which is designed to work with existing packaging and workflows while producing deterministic authentication results and scan data for later analysis. Public materials describe the solution as combining digital identity, mobile verification, and cloud analytics, but unable to source a separate regulatory clearance or clinical validation statement on the live site.

Why Do Leading Healthcare Teams Trust Digimarc?

• Digimarc says it has maintained a relationship with central banks for nearly 30 years, supporting currency anti-counterfeiting at global scale.

• Its 2024 annual filing states it works with numerous partners, including brand deployment providers, pre-media service providers, consumer packaging solutions companies, and scanner manufacturers.

• Digimarc has a partner ecosystem that includes printers, prepress firms, converters, system integrators, and digital agencies for packaging deployment.

• In October 2024, Digimarc announced a strategic partnership with a nutraceutical company to address counterfeit supplements online.

• In November 2024, Digimarc launched its Digital Security Solution for government programs, businesses, and citizens, combining digital watermarks, mobile authentication, and cloud services.

• In May 2026, Digimarc introduced provenance and verification infrastructure for autonomous AI workflows based on the C2PA standard.

• In 2023, AIM Global gave Digimarc’s Dom Guinard the Clive Hohberger Technology Award for contributions to automatic identification and data capture.

• In 2025, Digimarc was shortlisted as a finalist in the World Tobacco Awards for packaging-material innovation tied to its authentication solutions.

• Digimarc’s public materials emphasise that its technologies can be layered onto existing packaging and workflows, which may lower implementation friction for regulated buyers.

• Unable to source any FDA clearance, CE marking, ISO certification, or explicit HIPAA/GDPR alignment statement in the sources reviewed.